Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists

Patent metadata

Field	Value
Publication number	US-10294303-B2
Application number	US-201615387542-A
Country	US
Kind code	B2
Filing date	Dec 21, 2016
Priority date	Dec 23, 2015
Publication date	May 21, 2019
Grant date	May 21, 2019

Abstract

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

First claim

What is claimed is:

1. An isolated antigen binding protein that specifically binds to a human gastric inhibitory peptide receptor (GIPR) polypeptide, wherein said antigen binding protein is an antibody or a fragment thereof, and wherein said antibody comprises a CDRL1, a CDRL2, a CDRL3, a CDRH1, a CDRH2, and a CDRH3 wherein said. CDRL1 comprises SEQ ID NO: 702 ; said CDRL2 comprises SEQ ID NO: 859; said CDRL3 comprises SEQ ID NO: 1016; said CDRH1 comprises SEQ ID NO: 1173; said CDRH2 comprises SEQ ID NO: 1330; and said CDRH3 comprises SEQ ID NO: 1487.

2. The isolated antigen binding protein of claim 1 , wherein said human GIPR has a sequence comprising a sequence selected from the group consisting of SEQ ID NO: 3141, SEQ ID NO: 3143, and SEQ ID NO: 3145.

3. The isolated antigen binding protein of claim 1 or 2 , wherein said antigen binding protein is a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof.

4. The isolated antigen binding protein of claim 3 wherein, said antibody fragment is a Fab fragment, a Fab′ fragment, or a F(ab′)2 fragment.

5. The isolated antigen binding protein of claim 3 , wherein said antigen binding protein is a human antibody.

6. The isolated antigen binding protein of claim 3 , wherein said antigen binding protein is a monoclonal antibody.

7. The isolated antigen binding protein of claim 3 , wherein said antigen binding protein is of the IgG1-, IgG2- IgG3- or IgG4-type.

8. The isolated antigen binding protein of claim 7 , wherein said antigen binding protein is of the IgG1- or the IgG2-type.

9. The isolated antigen binding protein of any of claim 3 , wherein said antigen binding protein is coupled to a labeling group.

10. The isolated antigen binding protein of one of claim 3 , wherein said antigen binding protein inhibits binding of GIP to the extracellular portion of human GIPR.

11. The isolated antigen binding protein of claim 3 . wherein said antigen binding protein is an antibody or a fragment thereof, and wherein said antibody or fragment thereof comprises a light chain variable region comprising SEQ ID NO: 74 and a heavy chain variable region comprising SEQ ID NO: 231.

12. The isolated antigen binding protein of claim 3 , wherein said antigen binding protein is an antibody, and wherein said antibody comprises a light chain comprising SEQ ID NO: 388 and a heavy chain comprising SEQ ID NO: 545.

13. The isolated antigen binding protein of claim 1 , wherein said antibody comprises a CDRL1, a CDRL2, a CDRL3, a CDRH1, a CDRH2, and a CDRH3, wherein said CDRL1 consists of SEQ ID NO: 702 ; said CDRL2 consists of SEQ ID NO: 859; said CDRL3consists of SEQ ID NO: 1016; said CDRH1 consists of SEQ ID NO: 1173; said CDRH2 consists of SEQ ID NO: 1330; and said CDRH3 consists of SEQ ID NO: 1487.

14. A pharmaceutical composition comprising at least one antibody or fragment thereof according to any one of claims 1 , 11 , 12 , and 13 , and pharmaceutically acceptable excipient.

Assignees

• Amgen Inc

Inventors

• Yie Junming
• Shi Donghui
• Lloyd David J
• Wang Jinghong
• Sivits Jr Glenn N
• Veniant-Ellison Murielle M
• Komorowski Renee
• Agrawal Neeraj
• Bates Darren L
• Clavette Brandon C P
• Foltz Ian N
• Ho Shu-Yin
• Murawsky Christopher
• Min Xiaoshan
• Wang Zhulun

Classifications

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title